P Baas
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010
Felip E, Gridelli C, Baas P, Rosell R, Stahel R, Panel members. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011; 22:1507-1519.
01.07.2011Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010
01.07.2011Ann Oncol 2011; 22:1507-1519
Felip E, Gridelli C, Baas P, Rosell R, Stahel R, Panel members
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
Jörger M, Beijnen J, Huitema A, Rosing H, Vainchtein L, Jansen R, Smits P, Doodeman V, Baas P, Burgers J, Schellens J. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2011; 69:25-33.
18.05.2011Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
18.05.2011Cancer Chemother Pharmacol 2011; 69:25-33
Jörger Markus, Beijnen J H, Huitema A D R, Rosing H, Vainchtein L D, Jansen R S, Smits P H M, Doodeman V D, Baas P, Burgers J A, Schellens J H M
Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy
Jörger M, deJong D, Burylo A, Burgers J, Baas P, Huitema A, Beijnen J, Schellens J. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer 2011; 74:310-7.
29.04.2011Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy
29.04.2011Lung Cancer 2011; 74:310-7
Jörger Markus, deJong D, Burylo A, Burgers J A, Baas P, Huitema A D R, Beijnen J H, Schellens J H M
Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients
Jörger M, Huitema A, van den Bongard H, Baas P, Schornagel J, Schellens J, Beijnen J. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. British journal of clinical pharmacology 2006; 62:71-80.
01.07.2006Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients
01.07.2006British journal of clinical pharmacology 2006; 62:71-80
Jörger Markus, Huitema A D R, van den Bongard H J G D, Baas P, Schornagel J H, Schellens J H M, Beijnen J H